07.03.2024 14:48:43
|
Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal
(RTTNews) - Drug major Johnson & Johnson (JNJ) announced Thursday that it has completed the acquisition of Ambrx Biopharma, Inc. in an all-cash merger deal for a total equity value of around $2.0 billion, or $1.9 billion net of estimated cash acquired.
The transaction will be accounted for as a business combination.
Ambrx Biopharma is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates or ADCs.
The acquisition would help Johnson & Johnson to design, develop and commercialize targeted oncology therapeutics.
According to the firm, Ambrx's proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side effects typically associated with chemotherapy.
Yusri Elsayed, Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine, said, "We look forward to continuing the development of ARX517, which represents a potential first- and best-in-class PSMA-targeting ADC for the treatment of metastatic castration-resistant prostate cancer. This significant opportunity sets the stage for advancing next generation ADCs with the aim of delivering differentiated solid tumor therapies that improve patients' lives."
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
17.12.24 |
NYSE-Handel Dow Jones am Dienstagnachmittag mit Abgaben (finanzen.at) | |
17.12.24 |
Dow Jones-Handel aktuell: Dow Jones fällt (finanzen.at) | |
16.12.24 |
Schwacher Handel in New York: Dow Jones schlussendlich in Rot (finanzen.at) | |
11.12.24 |
Angespannte Stimmung in New York: Dow Jones beendet die Mittwochssitzung im Minus (finanzen.at) | |
11.12.24 |
Schwache Performance in New York: Dow Jones notiert nachmittags im Minus (finanzen.at) | |
11.12.24 |
Zuversicht in New York: Dow Jones mit Kursplus (finanzen.at) | |
11.12.24 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger mit einem Investment in Johnson Johnson von vor 10 Jahren verdient (finanzen.at) | |
11.12.24 |
Schwacher Wochentag in New York: Dow Jones zum Start des Mittwochshandels in der Verlustzone (finanzen.at) |